Current management practices for hyponatremia (HN) are incompletely understood. The HN Registry has recorded diagnostic measures, utilization, efficacy, and outcomes of therapy for eu-or hypervolemic HN. To better understand current practices, we analyzed data from 3087 adjudicated adult patients in the registry with serum sodium concentration of 130 mEq/l or less from 225 sites in the United States and European Union. Common initial monotherapy treatments were fluid restriction (35%), administration of isotonic (15%) or hypertonic saline (2%), and tolvaptan (5%); 17% received no active agent. Median (interquartile range) mEq/l serum sodium increases during the first day were as follows: no treatment, 1.0 (0.0-4.0); fluid restriction, 2.0 (0.0-4.0); isotonic saline, 3.0 (0.0-5.0); hypertonic saline, 5.0 (1.0-9.0); and tolvaptan, 4.0 (2.0-9.0). Adjusting for initial serum sodium concentration with logistic regression, the relative likelihoods for correction by 5 mEq/l or more (referent, fluid restriction) were 1.60 for hypertonic saline and 2.55 for tolvaptan. At discharge, serum sodium concentration was under 135 mEq/l in 78% of patients and 130 mEq/l or less in 49%. Overly rapid correction occurred in 7.9%. Thus, initial HN treatment often uses maneuvers of limited efficacy. Despite an association with poor outcomes and availability of effective therapy, most patients with HN are discharged from hospital still hyponatremic. Studies to assess short-and long-term benefits of correction of HN with effective therapies are needed. Hyponatremia (HN), defined as a serum sodium concentration ([Na þ ]) below the lower limit of normal, is the most common electrolyte disorder in hospitalized patients, with a prevalence as high as 30-42%. 1,2 HN is independently associated with mortality in congestive heart failure (CHF), cirrhosis, and hospitalized patients in general 3-7 and with increased hospital costs and readmission rates. 8, 9 Chronic HN has been linked to impaired gait and balance, increased falls and fracture rates, and osteoporosis. 10-13 However, a causal role of HN for these associations is largely unproven. 14 Correction of severe HN of sudden onset can be genuinely lifesaving, 15, and treatment of chronic HN associated with neurological symptoms is undeniably beneficial. Despite the widespread clinical impression that correction of less severe chronic HN is also worthwhile, evidence-based data demonstrating clinical benefit are limited. 10, [16] [17] [18] Hypovolemic HN responds readily to volume repletion. Until recently, treatment of hypervolemic HN has been limited to fluid restriction (FR) and correction of the underlying disorder. Treatment modalities for euvolemic HN have included FR, hypertonic saline (HS), loop diuretics, demeclocycline, and urea. With the approval of the vasopressin-receptor antagonists conivaptan and tolvaptan, more targeted treatment for euvolemic and hypervolemic HN became available. It remains uncertain how treatment options are employed, and how correction magnitude and incidence of adverse outcomes are affected by the type of therapy. With this background, the multinational HN
Hyponatremia (HN), defined as a serum sodium concentration ([Na þ ]) below the lower limit of normal, is the most common electrolyte disorder in hospitalized patients, with a prevalence as high as 30-42%. 1,2 HN is independently associated with mortality in congestive heart failure (CHF), cirrhosis, and hospitalized patients in general [3] [4] [5] [6] [7] and with increased hospital costs and readmission rates. 8, 9 Chronic HN has been linked to impaired gait and balance, increased falls and fracture rates, and osteoporosis. [10] [11] [12] [13] However, a causal role of HN for these associations is largely unproven. 14 Correction of severe HN of sudden onset can be genuinely lifesaving, 15 , and treatment of chronic HN associated with neurological symptoms is undeniably beneficial. Despite the widespread clinical impression that correction of less severe chronic HN is also worthwhile, evidence-based data demonstrating clinical benefit are limited. 10, [16] [17] [18] Hypovolemic HN responds readily to volume repletion. Until recently, treatment of hypervolemic HN has been limited to fluid restriction (FR) and correction of the underlying disorder. Treatment modalities for euvolemic HN have included FR, hypertonic saline (HS), loop diuretics, demeclocycline, and urea. With the approval of the vasopressin-receptor antagonists conivaptan and tolvaptan, more targeted treatment for euvolemic and hypervolemic HN became available. It remains uncertain how treatment options are employed, and how correction magnitude and incidence of adverse outcomes are affected by the type of therapy. With this background, the multinational HN Registry was initiated to assess the current state of treatment of euvolemic and hypervolemic HN in diverse, real-world hospital settings. Its specific purpose was to determine which diagnostic and treatment modalities are currently employed, how effective they are, and how rapidly and reliably they result in an increase in [Na þ ]. An additional goal was to determine which treatments posed the greatest risk of overly rapid correction and osmotic demyelination. 19 
RESULTS

Characteristics of study population
A total of 5028 patients were entered ( Figure 1 ) between September 2010 and February 2013. One or more criteria requiring adjudication were met by 2705 patients (54% of those entered), and 1941 of those (72%) failed adjudication. The 764 patients (28%) retained after adjudication and the 2323 (46% of those entered) not requiring adjudication comprise the 3087 individuals of the per-protocol data set. A sensitivity analysis performed with and without the 951 potentially hypovolemic patients excluded because of thiazide use or evidence of volume depletion showed no significant differences in rates of [Na þ ] change or achievement of [Na þ ] correction benchmarks. The syndrome of inappropriate antidiuretic hormone (SIADH), CHF, and cirrhosis data sets include patients in whom these diagnoses were made by treating physicians. Patient demographics and baseline characteristics are shown in Table 1 . Patients with cirrhosis were younger and more likely to be male compared with patients with SIADH or CHF. A prior episode of HN was known to have occurred in 909 patients (29%) and was most likely in patients with cirrhosis and least likely in those with SIADH. Most patients (71%) were under the care of a generalist rather than an internal medicine subspecialist.
Diagnosis
In the 1524 patients with SIADH, serum osmolality was measured in 66%, urine osmolality in 68%, and urine [Na þ ] in 63%; all three tests were performed in 47%, and none in 11%. Cortisol was measured in 33% of patients and thyroidstimulating hormone in 64%. All five of these measurements were made in 21% of patients.
Treatment selection
As shown in Adjudication not required n =2 323 (46%)
Adjudication criteria met n =764 (28%)
Per-protocol population n =3 087 (61%) 
moderate HN and 25% with mild HN (Po0.001). Stopping a medication that may induce SIADH could also be considered an active treatment; of the 509 patients who received no active HN therapy, 265 (52%) were receiving a potentially HN-inducing medication (see Supplementary Table S1 online for list), which was discontinued in 29 (11%).
The therapies utilized, according to underlying diagnosis or severity of HN, are shown in Figures 2 and 3 . Overall, 55% of patients were treated with FR or isotonic saline (NS) or both. Treatments more likely to result in an increase in [Na þ ]-HS or tolvaptan-were used in 7% of patients.
FR alone was selected most frequently. NS alone or with FR was used significantly more often in patients with SIADH (30%) than with CHF (7%) or cirrhosis (10%). Patients with lower baseline [Na þ ] were more likely to receive HS.
Treatment efficacy and outcomes
When used as a monotherapy, FR was least effective, although more rigorous FR (p1000 ml/day) resulted in a more rapid In some categories, the number of cases was quite small.
As FR was the most frequently prescribed initial therapy, we separately analyzed the course of patients after FR. A total of 922 patients (30%) with a baseline [Na þ ] o130 mEq/l were treated with FR initially ( Figure 5 ). The majority did not correct [Na þ ] by an increment X5 mEq/l and the majority of those patients received no additional treatment.
Overly rapid correction of [Na þ ] occurred in 7.9% of patients overall (Table 5 ) and was most likely in patients with SIADH (10.7%) and least likely with cirrhosis (3.6%; Po0.001, SIADH vs. cirrhosis). Of patients who received no active therapy, 1.4% experienced overly rapid correction. Compared with no therapy, the relative risk (95% confidence interval) for overly rapid correction was 1.6 (0.70-3.57) for FR, 2.35 (0.97-5.65) for NS, 12.01 (5.14-28.04) for HS, and 8.57 (3.84-19.12) for tolvaptan. Overall, 17.1% of patients receiving HS and 10.8% of patients receiving tolvaptan monotherapy at any time (P ¼ 0.08, HS vs. tolvaptan) experienced overly rapid correction, similar to the results for initial treatment responses (Table 3) . Included among the overly rapid correction episodes that occurred with active therapy are one episode with HS and two with tolvaptan in patients who were also receiving variable doses of desmopressin to treat diabetes insipidus post parasellar surgery. A further six episodes with tolvaptan occurred after suprasellar or pituitary procedures alone. In total, six of these postoperative cases occurred at a single center. The group with the lowest starting [Na þ ] was at greatest risk for overly rapid correction: 3.6% for mild HN (referent), 5.0% (relative risk 1.39 (95% confidence interval 0.94-2.06)) for moderate HN, and 19% (5.34 (3.86-7.40)) for severe HN. No cases of the osmotic demyelination syndrome were documented in the HN Registry.
A generalist or specialist other than an HN specialist (i.e., nephrologist or endocrinologist) served as attending physician for 2775 patients. Of this subset, 619 of 1035 patients (60%) for whom a HN specialist was consulted versus 767 of 1720 (45%) for whom no HN specialist was consulted were discharged with [Na þ ] 4130 mEq/l (Po0.001).
The mean length of stay was 10.3 ± 9.2 days for the group as a whole and did not vary by category of [Na þ ], diagnosis, or treatment employed. Comparisons of median length of stay for patients on any monotherapy tended to be longer for the group of patients not discharged until [Na þ ] was 4130 mEq/l (Supplementary Figure S1 online). Correction of HN to [Na þ ] 4130 mEq/l was not associated with survival; 7% of all patients who corrected versus 8% who did not correct (P ¼ 0.58) died or were discharged to hospice care. 
DISCUSSION
The HN Registry is the largest observational HN study to date and unique in its examination of the diagnosis, treatment, and outcome of HN in diverse hospital settings in the US and EU. Several important and novel findings have emerged from analysis of the results.
Determining the cause of HN is the first step in evaluating patients with HN and is crucial to guiding correct management. [20] [21] [22] Specific testing is generally not required with hypervolemic HN, but proper diagnosis of SIADH requires measurement of urine and plasma osmolality and urine [Na þ ] at a minimum. 20, 22, 23 Only 47% of patients with SIADH as identified by treating physicians had all three cardinal tests performed, and 11% underwent none. The full diagnostic criteria include normal thyroid and adrenal function, 24 but only 21% of identified SIADH patients underwent cortisol and thyroid hormone determinations, along with the required electrolyte and osmolality measurements. These results confirm previous findings of smaller single-center studies. 25, 26 The failure to make a precise diagnosis could have important sequelae.
HN has been associated with poor outcomes and higher hospital costs. 3, 4, [6] [7] [8] 10 Correction of HN in selected patients with CHF is associated with improved survival, 16, 17 and improved long-term survival following correction of HN in patients in general has been observed. 27 Experimentally, HN has been shown to have direct effects on cardiac fibrosis and myocyte function. 28, 29 HN at hospital discharge is associated with risk of readmission. 17 Despite the suggestion from these studies that HN is deleterious, the results of the HN Registry strongly infer that clinicians are not presently convinced that correction of HN is worthwhile. Fully 17% of patients received no specific treatment for HN beyond discontinuing potentially HN-inducing medicines or treating conditions like pain, pneumonia, or CHF that may lead to HN. Furthermore, more than three quarters of patients were discharged still hyponatremic. Even using a less stringent criterion, only half of the patients overall reached a [Na þ ] 4130 mEq/l by the time of discharge. Among the 56% of patients treated initially with FR alone who failed to increase [Na þ ] by 45 mEq/l, the treating physicians selected a second treatment in only 44%.
In the HN Registry, the choice of treatment, like the choice of diagnostic studies, was left up to the treating physicians. FR was used most often as the initial therapy irrespective of the etiology of the HN. This therapy is unlikely to result in an increase in [Na þ ] if urine osmolality is high (i.e., 4500 mOsm/kg H 2 O), or the ratio of urine-to-plasma electrolyte concentrations is 41.0, but these parameters were rarely evaluated. 20, 21, 30, 31 Among patients in the HN Registry, over the first day of its use as monotherapy, FR led only to a very modest rise in [Na þ ], 2.0 mEq/l. Characterization of the categorical responses of individual patients showed that 8% treated initially with FR or NS actually experienced further decreases in [Na þ ] exceeding 2 mEq/l, indicating that relying on these treatments alone can be detrimental. HS and tolvaptan worked more consistently ( Figure 4 ) and significantly faster compared with FR (Table 3 ). These agents also had very low rates of decreases in [Na þ ] (Figure 4 ). When examined in the patients as a whole, HS and tolvaptan had similar efficacy in increasing [Na þ ] by X5 mEq/l and were each more effective compared with FR or NS. Baseline [Na þ ] varied significantly between treatments, in some cases with little overlap (Table 3) . Achievement of correction benchmarks was high with no therapy (Table 4) , likely because of confounding by indication; clinicians probably added specific treatment for patients whose [Na þ ] did not rise spontaneously concomitant with resolution of the precipitant for HN. Indeed, detailed review of response according to categorical baseline [Na þ ] (data not shown) demonstrated that the majority of such patients underwent withdrawal of an agent that would interfere with water excretion or underwent treatment for congestion in CHF, events that would not be captured as specific therapy for HN in the computerized analysis. After adjustment for baseline [Na þ ] using logistic regression, tolvaptan was consistently better compared with FR in achieving all of the prespecified [Na þ ] correction benchmarks, and HS was more often associated with a [Na þ ] increment X5 mEq/l. This is consistent with clinical practice in which HS is used to with receiving other treatments. Pituitary surgery, a situation where SIADH may be transient and resolve suddenly, as well as concomitant use of desmopressin for diabetes insipidus appear to pose a particular risk for overly rapid correction when active therapies are used as well. Although well described with HS, only one case of osmotic demyelination syndrome with the use of a vasopressin-receptor antagonist as monotherapy to correct HN has been reported to date. 20, 33 No cases of osmotic demyelination syndrome were observed in the 5028 patients in the HN Registry.
The HN Registry has a number of limitations, most of which derive from its observational design. 16 Patients with hypovolemic HN were excluded, as were those with hypervolemic HN in the EU cohort. A large number of patients were excluded at the time of adjudication. Sensitivity analysis showed no difference in the major outcomes when patients with suspected hypovolemia were restored to the analysis. We believe that the exclusion of these patients represents a conservative approach. Ascertainment varied from center to center; enrollment of consecutive cases was not required. Consequently, the study provides no information about relative prevalence of different etiologies of HN. 34 Accurate determination of clinical volume status is difficult under the best of circumstances. The selection of diagnostic studies and treatments was left up to the clinicians responsible for patients, and the study relied on treating clinicians to make a diagnosis. Neither a fluid challenge nor a urine sodium determination was required as an entry criterion for putatively Any use includes any therapy period during which specified treatment was received irrespective of whether another treatment was also received. euvolemic patients. This limited our ability to exclude hypovolemia and independently confirm the presence of SIADH with precision. Because the study's intent was to capture 'real-world' practice, this limitation did not detract from observing how clinician-diagnosed SIADH is treated. Indeed, a principal conclusion is that diagnostic rigor in the case of SIADH is severely lacking, even in a study situation where some treating physicians were aware that their diagnostic choices were being observed. Some therapies were used too infrequently to assess. For example, urea, a treatment shown to be effective in SIADH, 35 and recommended in recent EU guidelines, 22 was used in only 10 patients. Because of the large number of combinations used at low frequency, analysis focused on monotherapy and initial therapy episodes. The study did not specify, much less randomize, treatment choices. We were unable to determine the rationale for choosing a particular treatment. In particular, we could not determine how often NS was used initially in a diagnostic trial to exclude volume depletion in patients suspected of SIADH, a reasonable strategy for its use. 20 Choice of treatments was likely confounded by indication, and the study cannot accurately assess whether any particular treatment shortened hospital stay. We were not able to fully assess how maneuvers such as discontinuation of a HN-inducing medication or treatment of CHF affected [Na þ ] changes or the decision to add another treatment maneuver. As a result, even the limited comparisons showing superiority or inferiority of particular treatments that were feasible must be interpreted with much circumspection.
In summary, despite the high prevalence of HN, 1,2 and published guidance on its diagnosis and treatment, [20] [21] [22] numerous shortcomings in current HN management are evident. HN in general and SIADH in particular are often diagnosed without attention to accepted diagnostic criteria. Strikingly, many patients receive no specific treatment for HN. FR was predictably the most frequent initial therapy but was ineffective in more than half of the cases. When unsuccessful, FR was often not followed with an additional therapy. Despite the availability of active therapies to correct [Na þ ], HS, and vasopressin-receptor antagonists, clinicians typically discharge patients with unresolved HN. From this study, we can conclude that educational efforts should focus on how to diagnose SIADH with rigor, on the lack of efficacy of FR alone and the potential for [Na þ ] to fall with FR alone, on the use of active treatments to raise [Na þ ] urgently when needed, and on increasing the awareness of situations where overly rapid correction is likely. One such circumstance highlighted in the present study is the immediate postoperative period after pituitary surgery where SIADH may occur but be transient and diabetes insipidus requiring desmopressin may supervene. Here, concomitant treatment with active therapies may pose a special risk. Randomized controlled trials of HN therapy are needed to compare relative efficacy, risks of over rapid correction, and overall costs, particularly for the active treatments. Given the strong association of HN with adverse outcomes, but persisting uncertainty about whether HN contributes to the poor outcomes or is only a marker of severe underlying disease, 3, 4, 6, 7, 10, 14 research efforts should, in addition, focus on which patients are more likely to respond to specific therapies and which will directly benefit from correction of HN.
MATERIALS AND METHODS
Study plan
The study design has been described previously in detail. 19 Briefly, patients with euvolemic or hypervolemic HN were enrolled from 146 US sites and patients with euvolemic HN were enrolled from 79 EU sites. We excluded patients with hypovolemic HN because this disorder should respond readily and completely to treatment of volume deficits, and it therefore poses no therapeutic dilemma. We excluded patient with hypervolemic HN from the EU study centers because tolvaptan is only approved in the EU for euvolemic patients. Inclusion of hypervolemic patients treated with tolvaptan would have created a regulatory burden for the sponsor. At each site, approval was sought from the appropriate research ethics review boards as required. After informed consent, absent a waiver, investigators prospectively recorded patient data. To ascertain patients, some centers systematically reviewed hospital laboratory-generated lists of patients with HN. Others enrolled only patients referred to or managed by the investigator personally. The study was exclusively observational; no standardized diagnostic or treatment protocols were imposed. Investigators simply recorded the choices made by the physicians responsible for the patient's hospital care.
Inclusion and exclusion criteria
To assure that HN was clinically significant, the study required an entry [Na þ ] p130 mEq/l. Patients were excluded if o18 years old, hypovolemic, hypervolemic (EU only), using an investigational agent or device, or if hyperglycemic enough to interfere with assessment of [Na þ ] or receiving renal replacement therapy while hyponatremic. As indicated in Supplementary Table S3 online, euvolemia was defined as the absence of clinical and historical evidence of extracellular fluid volume depletion or sequestration, and the absence of edema and ascites, or on the basis of the treating physician's diagnosis of SIADH. Hypervolemia was defined as excess extracellular fluid volume manifesting as dependent edema or ascites. Although not a specified exclusion criterion originally, we subsequently decided to exclude any patient who was receiving a thiazide at the time the treating physician made a diagnosis of SIADH. It would be difficult to assure that such patients were not in fact hypovolemic, 36 and diuretic use is generally considered to be an exclusion to the proper diagnosis of SIADH. 20 This decision was made prior to data analysis. A complete listing of inclusion and exclusion criteria, as published previously, is provided as Supplementary Table S3 online. 19 
Data collection
Principal data collection items included the following: admitting diagnosis; volume status; time of hospitalization; demographics including age (in years of age, except as 489 years if X90 years old) gender, and race; severity of the underlying condition using standard measures; etiology for SIADH including tumor, CNS disorder, drug induced, pulmonary disease, other specified cause, idiopathic (cause sought but not found), or unknown; history of prior HN; and acuity of onset of HN, if known. HN-inducing medications, HN treatment medications, diuretics, other medications, vital signs including blood pressure and heart rate at admission or onset of HN and discharge, input and output measurements, daily weights, type and volume of intravenous fluids administered, and FR limits were also recorded. Any isonatric fluid was considered to be NS for purposes of analysis. Serum osmolality, [Na þ ], blood urea nitrogen, creatinine, and glucose values were recorded daily as available, as were urine osmolality and [Na þ ] and the results of testing performed to elucidate the cause of HN or to assess severity of comorbidities including serum potassium, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, total protein, thyroidstimulating hormone, cortisol, albumin, total bilirubin, and uric acid; adrenocorticotropic hormone, B-type natriuretic hormone, and N-terminal pro-B-type natriuretic peptide; hematocrit, hemoglobin, prothrombin time, and international normalized ratio; and urine urea nitrogen. Comorbidity procedures; HN symptoms; conditions developing during hospitalization; intensive care unit, intermediate care unit, and emergency department stay information; treating physician specialty and subspecialist consults for HN were also collected. Race was classified by the investigators (US only) and assessed to see whether race affected treatment or outcome. The following were also collected at discharge: timing of discharge, discharge diagnoses, disposition, discharge location, early termination reason (if applicable), and possibility of earlier discharge.
Adjudication
To assure that entry criteria were met and that duration of HN was evaluable, data from patients who met a prespecified review threshold were subject to review by two members of the study Steering Committee. Discrepancies were resolved by review by the Steering Committee co-chairmen. Prespecified criteria triggering adjudication are listed in Supplementary Table S4 online. 19 Among those who failed adjudication and were excluded were as follows: (1) individuals stated to be euvolemic but who presented with elevated blood urea nitrogen:creatinine ratios and/or low urine [Na þ ]s whose HN responded to administration of NS alone coincident with a fall in blood urea nitrogen:creatinine ratio; (2) individuals who were stated to be euvolemic but whose admission findings included edema or anasarca; (3) individuals with only a single [Na þ ] o130 mEq/l who did not receive an active treatment for HN, and (4) patients with a qualifying episode of euvolemic or hypervolemic HN who also had a separate episode of hypovolemic HN during the same hospitalization that would have interfered with computerized parsing of data.
Statistical methods
Therapy periods are defined as the time interval during which a patient received only the single therapy (monotherapy) or combination specified. Patients could have had multiple episodes and multiple therapies during the hospital stay. Initial therapy refers to the first treatment given specifically for HN. Conivaptan was used initially in only 6 patients and urea was used in only 10 but never as initial therapy. Thus, we were unable to quantitate response to these agents. Duration of the initial course of HN therapy was determined by subtracting the treatment day number of the first day the initial HN therapy was used from the treatment day number of the day the treatment ended and adding one.
Categorical variables were compared using a chi-square test. In the case of more than two comparison groups, an overall w 2 -test was conducted before performing individual pairwise w 2 -tests. Analysis of correction criteria to test for treatment differences was performed using a logistic regression model to adjust for the baseline [Na þ ] levels. Analyses were performed separately using 'no therapy' and 'fluid restriction' as references for comparisons with the other treatments.
Nonparametric analysis was performed for continuous variables. When there were more than two comparison groups, a KruskalWallis test was conducted to generate an overall test for equality of medians. Pairwise group comparisons were then carried out. For comparisons of only two groups, medians were compared using the Wilcoxon rank-sum test. P-values were not adjusted for multiple comparisons. Data are reported as medians with interquartile range.
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